Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab-Reference-Cited by-同舟云学术

Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab

Published:2012-10-16 Issue:5 Volume:54 Page:959-966
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Powell James R.,Dojcinov Stefan,King Louise,Wosniak Sue,Gerry Stephen,Casbard Angela,Bailey Hazel,Gallop-Evans Eve,Maughan Tim

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2012.733875

Reference31 articles.

1. Cancer in older persons: an international issue in an aging world

2. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

3. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

4. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

5. Hypoxia — a key regulatory factor in tumour growth

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma;International Journal of Molecular Sciences;2023-03-13

2. Hypoxia‐targeting therapy for intestinal T‐cell lymphoma in dogs: Preclinical study using 3D in vitro models;Veterinary and Comparative Oncology;2022-08-19

3. Sustain, Adapt, and Overcome—Hypoxia Associated Changes in the Progression of Lymphatic Neoplasia;Frontiers in Oncology;2019-11-21

4. Anti-angiogenic effects of biotechnological therapies in rheumatic diseases;Biologics: Targets and Therapy;2017-12

5. Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition;PLOS ONE;2017-05-10